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L&HCP Faculty Awarded NIH Grant to Study
Regulation of Microbiota Transplantation
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The project builds on Hoffmann’s prior NIH grant that assessed the
regulatory framework for probiotics (or live microorganisms which when
administered in adequate amounts confer a health benefit on the host) in
the United States by convening a multidisciplinary Working Group to
provide a critical review of current probiotic regulation. From 2009 to
2014, Hoffmann and her co-investigators studied how the Food and Drug
Administration (FDA) should regulate probiotics under a grant funded by
NIH’s Human Microbiome Project (HMP), a $150 million NIH initiative
to characterize the microbial communities found at several different sites
on the human body and to analyze the role of these microbes in human
health and disease. Until recently, the abundant community of humanassociated microbes (which outnumber human cells by about ten to one)
was largely unstudied, leaving their influence upon human development,
physiology, immunity, and nutrition almost entirely unknown. The HMP
was established to support the comprehensive characterization of the
human microbiota and analysis of their role in human health and disease.
Advances in DNA sequencing technologies have created the field of
metagenomics that allows analysis of genetic material harvested directly
from microbial communities. HMP scientists are using metagenomics
and genetic analyses of available reference microbial strains to understand
the complexity of human-associated microbial communities and how
the microbiome and human host interact to support health or to trigger
disease. One of the most significant outgrowths of the HMP is advanced
research into probiotics.
A portion of HMP funds was set aside to study the Ethical, Legal, and
Social Implications (often referred to as the ELSI issues) of the HMP’s
scientific goals and these early HMP grants were administered by the
National Human Genome Research Institute (NHGRI). Both Hoffmann’s
2009 and 2015 awards were ELSI grants. The first was awarded by
NHGRI and the most recent by the National Institute of Allergy and
Infectious Diseases. Hoffmann's collaborators on the probiotic grant
were Drs. Palumbo and Ravel (along with Dr. Claire Fraser, Professor and
Director, Institute of Genome Sciences, University of Maryland School
of Medicine, and Jack Schwartz, Adjunct Professor at University of
Maryland Carey School of Law) which led to numerous publications and
follow-on work (see box, page 6).
In addition to the development of probiotic therapies, advances in
our understanding of the human microbiome are also likely to make
microbiota transplants – or transplantation of bacteria from a healthy
individual to a patient recipient to cure or manage a health condition increasingly common. At present, there is much interest and evidencebased support for one type of microbiota transplant: fecal microbiota
transplantation (FMT). FMT involves the transplantation of fecal
material into a patient recipient to treat various severe intestinal
disorders. Interest in FMT is growing as strong evidence is emerging
that FMT is effective in treating Clostridium difficile infection and may
also be effective in treating other gastrointestinal conditions. FMT has
been discussed widely in Atlantic Magazine (“When Feces Is the Best
Medicine”), the New Yorker (“The Excrement Experiment”), and the
New York Times (“When Pills Fail, This, er, Option Provides a Cure”).
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FMT is most commonly performed via colonoscopy
using fecal material that is typically donated by
a relative or partner and tested in advance for
bloodborne infectious agents. There is growing
interest in administering the treatment in pill form
for patients who may not be able to tolerate another
delivery system and to make the treatment more
palatable from an aesthetic and procedural perspective.
At least one stool bank has been created to collect
stool samples from healthy, pre-screened individuals,
process the donations, and sell the product to clinics
and there appears to be growing interest in this type
of venture. Other researchers are working on a
cocktail of gastrointestinal bacteria collected from
healthy volunteers and grown in the lab (to mimic the
microbiome) that can be delivered in pill form. This
has been referred to as “synthetic feces”.
FMT is raising new legal and regulatory questions
for FDA. At present, via draft guidance released
in July 2013, FDA stated that it would exercise
enforcement discretion allowing physicians to use
FMT to treat Clostridium difficile infection in patients
who have not responded to standard therapies without
filing an investigational new drug (IND) application
with the agency. The enforcement discretion policy
does not extend to other uses of FMT so that a
physician wanting to use FMT for any other condition
must file an IND. The guidance notes that “FDA
intends to exercise this discretion on an interim basis
while the Agency further considers the matter.”
Although FMT is the focus of much attention,
emerging microbiota transplantation options
include vaginal, skin, oral, and anterior nares
transplantations. A further cutting edge use of
microbiota transplantation is "whole microbiome"
transplantation pioneered by Dr. Maria DominguezBello in which babies born via Cesarean section are
swabbed in material that is placed in the mother’s
birth canal during birth, allowing for babies to be
exposed to important bacteria present in the vaginal
canal. Dr. Dominguez-Bellow has speculated that lack
of exposure to these microbiota might explain why
C-section babies are at greater risk of developing Type
1 diabetes, celiac disease, asthma or obesity.1 Use of
these other microbiota transplantation options is still in
its infancy and there has been little, if any, discussion
in the literature as to their appropriate regulation.
Hoffmann’s project will provide a timely
examination of the appropriate regulatory path for
fecal and other types of microbiota transplantation.

Using the same research method that Hoffmann and
her collaborators used with their probiotics project,
Hoffmann will convene approximately 25 expert
stakeholders to form a Working Group that will
collaborate over the course of three meetings to craft
recommendations. The invited stakeholders who will
meet for the first time in Baltimore on December 3 and
4 include scientists, clinicians, patient and professional
association advocates, bioethicists, government
regulators, academics, lawyers, and individuals from
the biotechnology industries who have an interest
in microbiota transplantation or expertise relevant
to the proposed project. The Working Group will
evaluate alternative regulatory options for microbiota
transplantation and consider which regulatory
approach or approaches would work for these
procedures in a way that meets specific criteria for
regulatory effectiveness. Regulatory frameworks that
may be appropriate in whole or in part for microbiota
transplantation include the frameworks for regulating
biological products, blood and blood products,
vascularized organs, human cells, tissues and cellular
products. The Working Group will also consider
whether a hybrid or new regulatory scheme is best
to ensure the safety, effectiveness, and accessibility
of the procedures. The investigators will include a
description of the Working Group process and the
recommendations in a paper or series of papers.
____________
See interview with Dr. Dominguez-Bello regarding the preliminary
results of her research that were presented at the 2014 conference of the
American Society for Microbiology in Boston. WBUR radio interview,
June 25, 2014. http://commonhealth.wbur.org/2014/06/birth-canalbacteria-c-section
1
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NIH Microbiota Transplantation Grant

The Microbiota Research Team
Dr. Frank Palumbo

The answers to the questions we raise require an
interdisciplinary approach, including assessments
of treatment and procedures, basic scientific
knowledge, and regulatory pathways to facilitate
microbiota transplantation use.

Frank Palumbo,
Ph.D., JD, is a
professor at the
University of
Maryland School
of Pharmacy and
Executive Director of
the school’s Center
on Drugs and Public
Policy. He is also
an adjunct professor
at the University
of Maryland Carey
School of Law where
he teaches food and
drug law.

What excites you about participating in the project?
It is a new area that is suddenly garnering a great
deal of attention and I am honored to be part of
the early phase of research. And---I really enjoy
working with my colleagues.

Dr. Mary-Claire Roghmann

What is your
connection to the project from a professional
perspective and why did you become involved in it?
I had the pleasure of working with Diane
Hoffmann, Jacques Ravel, and Virginia Rowthorn,
among others, on an NIH probiotics project where
we assessed the current regulatory structure
surrounding probiotics and made recommendations
for regulatory changes.
What will you bring that is unique to the project?
I am a pharmacist-attorney with a particular
interest in food and drug law and have been
practicing and conducting research in that area for
many years.
Why do you think it’s important to study and make
recommendations about microbiota transplantation at
this point in history?
We are learning so much about the human
microbiome and are just scratching the surface of
possibilities in research and treatment. Along with
this comes federal and state law and regulation
to protect those who are subjects of the treatment.
Laws and regulations provide an approach
that may indeed lead to proof of safety and
effectiveness.
From your perspective, why is an interprofessional
approach important to studying how microbiota
transplantation should be regulated?

Dr. Mary-Claire
Roghmann is
a Professor of
Epidemiology &
Public Health at
the University of
Maryland School
of Medicine. She
is an infectious
disease physician
and clinical
investigator whose
research is focused
on understanding
bacterial and host
determinants of S.
aureus colonization,
transmission and infection with the goal of developing
better ways of preventing S. aureus infections,
including those caused by antibiotic resistant strains
such as MRSA.
What is your connection to the project from a
professional perspective and why did you become
involved in it?
I'm an infectious disease physician,
epidemiologist and researcher interested
in preventing infections. Manipulation of
our microbiomes is a novel approach to this goal
and microbiota transplantation is the first step
in this pathway.
What will you bring that is unique to the project?
My perspective as an infectious disease
physician focuses on prevention. In addition as
an epidemiologist, I bring a population-based
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perspective.
Why do you think it’s important to study and make
recommendations about microbiota transplantation
now (at this point in history)?
Now is the most important time to do this as we
enter a new era when people think about how
we could manipulate our microbiome to improve
health.

Dr. Erik Von Rosenvinge
Erik Von Rosenvinge,
MD, is an Associate
Professor of Medicine
in the Division of
Gastroenterology
& Hepatology at
the University of
Maryland School of
Medicine and Chief
of the GI Section
at the Veterans
Administration
Maryland Health
Care System. Dr.
Von Rosenvinge has
performed fecal
microbiota transplants on a number of his patients.
What is your connection to the project from a
professional perspective and why did you become
involved in it?
As a clinical gastroenterologist, I see patients
with diseases associated with alterations in the
gastrointestinal microbiome, such as intestinal
infections, Crohn’s disease, and irritable bowel
syndrome. One disease strongly linked to an
abnormal microbiome is Clostridium difficile
infection, a bacterial infection of the colon that
typically begins after taking antibiotics and can
cause severe diarrhea, toxic megacolon, and even
death. This infection has a tendency to relapse after
treatment and at times can be extremely difficult to
cure.
After observing patients miserable from this
disease, reading about ‘miracle cures’ from fecal
transplantation, and reviewing the emerging
scientific literature supporting the procedure, I
began offering this procedure to my patients and
have had great success. For a brief period the
FDA prevented me from providing this procedure
to my patients as they began requiring an IND

application that I, and most people performing the
procedure, did not have. After an outcry from the
medical community and patients, the FDA stopped
enforcing this policy for patients with C. difficile
infection not responding to conventional medical
therapy.
While I appreciate that I can again offer my
patients this procedure, I also appreciate the FDA’s
desire to regulate microbiota transplantations.
While altering a patient’s microbiome through
fecal transplantation has been shown effective for
Clostridium difficile infection, so far it has not
proven effective for other conditions, has risks, and
has been attempted for a myriad of conditions. I’m
optimistic that the Working Group convened under
this grant will help guide the FDA in a way that
helps them strike a balance that allows for these
procedures for conditions where they are proven
to work, fosters rigorous scientific research, and
maximizes patient safety.
What will you bring that is unique to the project?
As the only study team member that has performed
microbiota transplantations on patients, I have a
unique perspective on how they are performed and
what regulatory issues have arisen at our local
institution. I also have access to patients who can
share their experiences.
From your perspective, why is an interprofessional
approach important to studying how microbiota
transplantation should be regulated?
While seemingly simple, microbiota
transplantation is a complex process, especially
as currently performed. Is the donor microbiome
a drug? A biologic product? A tissue? And how do
you regulate a product for which the exact contents
are unknown and change with every sample? By
bringing together a broad team with expertise
in the scientific, clinical, legal, and regulatory
arenas, we hope to answer some of these important
questions.
Did you ever think you would be part of a project
initiated at the law school and how has been working
with lawyers been so far?
Having several lawyers in the family, who believe
they are correct ALL the time, I didn’t think I would
be part of a project initiated at the law school, but
so far it has been a lot of fun.
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Dr. Jacques Ravel
Dr. Jacques Ravel is
Professor of Microbiology
and Immunology at the
University of Maryland
School of Medicine and
Associate Director for
Genomics, Institute for
Genome Sciences. He
is a national leader in
microbial genomics and
grantee of several HMP
grants from NIH.
What is your connection to the project from a
professional perspective and why did you become
involved in it?
As a researcher working on understanding the role
of the human microbiome in health and diseases,
I worked with the team on a previous project
evaluating the regulatory framework for probiotics
in the US. My own work on the vaginal microbiome
is connected to both the use of probiotics and
microbiota transplants in order to restore vaginal
health.
What will you bring that is unique to the project?
My expertise is in understanding the functional role
of microbes in health and characterization of the
human microbiome. These are important aspects to
characterizing material to be transplanted and also
evaluating the success of a transplant.
From your perspective, why is an interprofessional
approach important to studying how microbiota
transplantation should be regulated?
Regulation involves many components from legal
aspects, to information for consumers, to technical
feasibilities, and, of course, regulation of product
safety. To capture nuances associated with all these
aspects, a multidisciplinary approach is essential.
Did you ever think you would be part of a project
initiated at the law school and how has been working
with lawyers been so far?
I never imagined myself working with faculty at the
law school. When they approached me about the
probiotics project, right away I saw the potential
for a true collaboration, and my expectations were
met. It has been a great experience. When they
contacted me to contribute to this project, I never
hesitated!

Diane Hoffmann Continues Work
on Probiotics
At the end of Professor
Hoffmann’s NIH grant
to study the regulation of
probiotics, Hoffmann and
her colleagues completed an
extensive white paper and
published articles in Science
and the Journal of Food and
Drug Law based on the paper.
Both written works described
the recommendations
that came from Working
Group meetings. Since the publication of the articles,
Hoffmann has continued to speak and write about
probiotics and other legal/ethical issues that came out of
her study of the HMP and regulation of probiotics.
Articles
• Diane E. Hoffmann (with Jack Schwartz) “Stopping
Deceptive Health Claims: The Need for a Private
Right of Action under Federal Law” (forthcoming in
American J. of Law & Med.)
• Diane E. Hoffmann (with C.M. Fraser, F.B. Palumbo,
J. Ravel, V. Rowthorn, & J. Schwartz) “Probiotics:
Achieving a Better Regulatory Fit,” 69 J. Food &
Drug L. 237 (2014)
• Diane E. Hoffmann (with C.M. Fraser, F.B. Palumbo,
J. Ravel, K. Rothenberg, V. Rowthorn,& J. Schwartz)
“Probiotics: Finding the Right Regulatory Balance,”
342 Science 314-315 (October 18, 2013)
• Diane E. Hoffmann (with Dennis Fortenberry
& Jacques Ravel), “Do potential changes to the
Common Rule adequately address new areas of
research: A case study focusing on the Human
Microbiome Project” 41 Journal of Law, Medicine &
Ethics 454 (Summer, 2013)
Lectures, Workshops & Speaking Engagements
• “Does Research on the Human Microbiome raise
unique ethical or legal issues?” Institute of Medicine
Annual Meeting, National Academy of Sciences
Washington, D.C. (Oct. 19, 2014)
• Federal Regulation of Probiotics, Microbiota &
Health Workshop, International Life Sciences
Institute, Washington, D.C. (April 27, 2015)
• “Federal Regulation of Probiotics: An Analysis of the
Existing Regulatory Framework” at FDA Symposium
"Linking the Microbiome to Health, Safety, and
Regulation," College Park, MD (September 29-30,
2015)
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It’s All Business to Some Health Law Graduates:
Innovative Ventures Created by Maryland Carey
Health Law Alums
Although most of our health law students graduate
and begin work in law firms or government positions,
some entrepreneurial former students have started
their own health-related businesses and all of them
credit their law degree as critical to their success. In
this article, we feature three former students who went
on to start their own businesses in three different,
highly regulated areas of health and health care.

M. Jason Brooke ’10, CEO & General
Counsel, Vasoptic Medical Inc.
Jason, a 2010
graduate of the
law school, was
a scientist before
he was a lawyer.
Before studying
law, Jason obtained
a BS in Biological
Resources
Engineering at
University of
Maryland College
Park and an MS
from Johns Hopkins
in Biomedical
Engineering. He
then worked as
a senior scientist
developing implantable pacemakers and defibrillators
for Boston Scientific Corporation.
As a law student, Jason externed at the Center for
Devices & Radiological Health at FDA and served as
Editor-in-Chief of the law school’s Journal of Health
Care Law & Policy. Upon graduation, he became
an Associate at the law firm of Epstein Becker &
Green (EBG) and, after several years of successful
practice focused on the medical device and mobile
health industries, Jason took the leap into the world of
entrepreneurship, leveraging his experience in medical
device development as a lawyer, biomedical engineer,
and scientist. His organization, Vasoptic Medical Inc.,
is commercializing technology that allows a doctor or
scientist to non-invasively evaluate blood flow in the

small blood vessels of any tissue that can be exposed
to light. Vasoptic is currently working on a product
line of retinal imagers that will allow scientists to use
their technology for research purposes and doctors to
diagnose and manage ophthalmic diseases that include
diabetic retinopathy (the leading cause of blindness in
American adults) and retinopathy of prematurity (one
of the leading causes of blindness in children around
the world).
Since starting the business a little over three years
ago, Brooke and his colleagues have made progress
on both business and technology development fronts.
Through close collaboration with the University of
Maryland Medical Center and the Johns Hopkins
University, the Vasoptic Team has been lucky enough
to win over $1M in grants from the National Institutes
of Health’s Small Business Innovative Research
(SBIR) Program to develop the retinal imaging
technology and to evaluate the use of their technology
in surgical settings. They also recently received a
$250,000 investment from the Abell Foundation,
a non-profit dedicated to the enhancement of the
quality of life in Maryland, with a particular focus on
Baltimore.
The company is now moving beyond the research
stage toward clinical testing and deployment. After
consultation, FDA recently determined that their
device is a “non-significant risk,” which means that
Vasoptic can evaluate the retinal imager in a clinical
setting without significant regulatory hurdles that
often accompany the evaluation of investigational
medical devices. Brooke has big dreams for
Vasoptic and hopes to see the company’s technology
impact the optical health of people in the US and
beyond. In addition to moving ahead on the business
front, Brooke and his colleagues are committed to
being involved in the community - Team Vasoptic
participates annually in the American Diabetes
Association’s Walk to Stop Diabetes to help fundraise
for the organization.
How did his legal training help get him where he
is today? According to Brooke, his legal training
“has been critical to Vasoptic’s success thus far.
The medical device industry, and healthcare more
generally, is heavily regulated. Understanding FDA
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regulations and CMS reimbursement requirements
(not to mention corporate governance rules), gives
us a leg up as an early stage company to ensure that
we are developing our technology to be safe and
effective to, ultimately, improve access to quality care
at lower costs for the millions of people who need
it most.” With such vision and passion for medical
device development, it is not surprising that Jason was
recently named one of Baltimore’s 40 Under 40 by the
Baltimore Business Journal.
  

Kylyn (Deary) Mead ’11, President and
CEO, Go Docs Go
When Kylyn was just two years out of law school,
she started her own “house call medicine” business
called Go Docs Go. She credits growing up in a
family that owned a home health care business and
a year as an attorney in the compliance department
at the University of Michigan Health System as the
foundation for her jump into business but, by any
judge, she is a risk taker and it looks like her risk has
paid off. Kylyn now runs a business that employs
40-45 employees and makes over 1500 house calls
each month to patients in Michigan and Indiana. Even
more impressively, she entered a relatively niche
area of health care delivery that is now starting to
turn heads in Washington as a way to save costs for
Medicare. Congress endorsed a house call medicine
demonstration project in the Affordable Care Act.
What is a house call medicine? Go Docs Go
provides health care in the home for people who
cannot travel to a health care facility because of age,
illness or disability. Go Docs Go uses physicians
and nurse practitioners to perform the same services
that a patient would receive in a traditional primary
care physician office setting, including diagnosis,
evaluation and treatment. The company also helps
coordinate medical care with other providers including
physical therapy and hospice care. For the most part,
Go Docs Go is paid by patients’ Medicare Part B
coverage. While it is primarily a geriatric practice,
Go Docs Go also has a number of younger veterans on
their rolls.
Kylyn’s biggest satisfaction from starting Go Docs
Go has been her ability to provide for her patients
beyond medical care. Patients who cannot get to the
hospital often have difficulty accessing social services
as well and often seek care in emergency rooms for

problems that could have been dealt with more easily
– and more cheaply – in the home. It’s for this reason
that CMS is studying house call businesses via their
Independence at Home program and considering how
to reward businesses that save money for Medicare.
At this point, the program is in the demonstration
stage, but Kylyn hopes her company will be able to
reap the benefits of the program in the future.
Kylyn’s legal training has been critical to her
success as a business leader. She notes that her
industry is highly regulated and that her legal
skills are critical during negotiations with the state,
insurance carriers and Medicare. Further, with all her
employees, she has to understand contracts, human
resources, and business law. Even when she does use
outside counsel, her legal training allows her to speak
comfortably with other lawyers. Overall, she credits
her legal training with her ability to approach any
problem with common sense.

Marcus Wang ’08, Co-Founder and
General Manager, ZytoGen
Global Genetics Institute
Although he
did not receive
the Health Law
Certificate as a
student, with the
launch of ZytoGen
Global Genetics
Institute in 2013,
Marcus Wang ’08
has joined the Law
& Health Care
Program family at
Maryland.
Wang partnered
with two globallyrenowned pioneers
in the field of
infertility medicine to found ZytoGen, a molecular
genetics laboratory providing Preimplantation Genetic
Screening (PGS) to patients and clinics in the United
States, Latin America, and Asia, through its CLIAcertified laboratory in Baltimore County. ZytoGen
uses PGS to screen embryos for chromosomal
abnormalities prior to implantation in the mother
during the IVF process. The screening empowers
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families to identify healthy embryos, lower the risk
of miscarriage, and increase the likelihood of a
successful pregnancy.
By optimizing conditions for single embryo transfer,
ZytoGen also allows women the choice of avoiding
the risks associated with multiple pregnancies,
including selective reduction. Known for its cutting
edge technology and rapid turnaround time, ZytoGen
continues to innovate, most recently by conducting
the world’s first randomized clinical study on the
efficiency of Next Generation Sequencing for PGS.
Despite his lifelong passion for business, Marcus
grew up with a great deal of interest in, and respect
for, the medical profession, which he sees as truly
helping people. Both his parents are physicians,
and his own interest in medicine spurred him to
premed coursework at Harvard University as an
undergraduate. Along with his interest in medicine,
Marcus brings his international business experience
to the operation of ZytoGen. Self-taught and fluent
in both Mandarin and Cantonese Chinese, Marcus
worked for the State of Maryland as an International
Investment and Trade Specialist for China before
coming to the law school and focusing on business
law. Upon graduation, he practiced corporate law at
the Manhattan office of DLA Piper before leveraging
his business and legal skills to manage Under

Armour’s expansion into the China market.
While he still consults for U.S. businesses
concerning China market entry, ZytoGen “completes
a dream” for Marcus. As a boy, his parents would
inspire him at the dinner table with stories of helping
their patients. Today, he is humbled to help families
fulfill their dreams. Recently, he spoke to a mother
who brought a healthy baby to term after getting the
green light from ZytoGen on a genetic screening.
Hearing the baby’s happy babbling in the background
of the call convinced Marcus that he is in the right
field.
How does he use the law in his position as head of
a health care company? He credits law school with
giving him a broad range of skills that have been
critical to handling the legal and regulatory issues
that are part of any start-up business, especially in the
health arena. In 2011, Mr. Wang was honored by the
Maryland Daily Record, Maryland's premier business
journal, as one of the “20 In Their 20s”, based on
“professional accomplishment, civic involvement and
impact of achievement.” In October, Marcus will be
speaking at the 30th anniversary of the L&HCP about
the future of health law, specifically the intersection
of law and biotechnology. What does the future hold
for Marcus? It’s likely something that will continue to
make us incredibly proud to call him an alum.

ACA regulations. HIPAA compliance. Insurance fraud and abuse.
Do you tackle these challenges at work?

Go further.

Enhance your career with a new Master of Science in Law. A specialization in Health
Care Law offers practical legal knowledge—and a competitive edge—to professionals
working at the intersection of law and health care.
An affordable part-time, evening program at the
University of Maryland, College Park.

http://www.law.umaryland.edu/msl
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Law School’s New Business Fellowship Program Features
Placements at Local Health Care Corporations
The University of Maryland Francis King Carey School of Law recently launched a Business Fellowship
Program to place law students and recent graduates in Baltimore-area businesses. The new initiative is
designed to help Maryland companies and institutions meet their business and legal needs while providing
growth opportunities for the next generation of law and business leaders. Three prominent health care
institutions are inaugural partners in the program. The University of Maryland Medical System (UMMS)
is sponsoring a year-long postgraduate fellowship which was awarded to 2015 health law graduate
Jaclyn Machometa. FutureCare, which operates nursing and rehabilitation centers across the Baltimore/
Washington area, and LifeBridge Health, which owns a number of local hospitals, are participating in the
10-week summer fellowship.
Modeled after the judicial clerkship and internship experience, the Maryland Carey Law Business
Fellowship Program offers fellows professional employment, mentoring, and a stipend with Baltimore-area
businesses or organizations. Fellows will work in a corporate counsel’s office or in business operations.
Given the number of health law students interested in these opportunities, other fellowships with healthrelated organizations in Baltimore are currently under negotiation.

Professor Kathleen Hoke’s Public Health Efforts Draw
$1 Million in Grant Funding
In addition to teaching the popular Public Health Law Clinic, Professor Kathleen
Hoke is also the Director of the Network for Public Health Law, Eastern Region and
the Director of the Legal Resource Center for Public Health Policy at the University
of Maryland Carey School of Law. The Network provides technical legal assistance
to public health professionals and their attorneys at all levels of government, while
the Legal Resource Center provides technical legal assistance to Maryland state and
local health officials and organizations working on tobacco control and other public
health issues. For FY 2016, the organizations have been awarded grants in excess
of $1 million to support their work. Below is a brief summary of the activities and
grants Professor Hoke and her staff are undertaking:
Legal Resource Center for Public Health
The Center will continue working under their 2001 grant from the Maryland Department of Health and Mental
Hygiene (DHMH) to provide legal support to communities, community groups, employers, local governments,
and State legislators and agencies interested in reducing the negative health consequences of tobacco use. In
addition, the Center will continue its injury prevention work that started in 2011 under a DHMH grant that is
part of the Centers for Disease Control (CDC)’s Core Violence and Injury Prevention Program.
Network for Public Health Law, Eastern Region
The Network was funded through a 2010 grant from the Robert Wood Johnson Foundation which has
continued to fund the Network with a current grant through 2017. The Network also has two grants from
the CDC. The first is in partnership with Change Lab Solutions and the National Alliance of State Pharmacy
Associations to examine effective approaches to the development of collaborative practice agreements between
physicians and pharmacists and to develop a case study on a state law expanding scope of practice laws for
allied health professionals. CDC also provided funds to the Network to study state efforts to address student
athletes’ return to the classroom after sustaining a concussion, as well as to update an existing database of state
youth sports-related traumatic brain injury laws. Finally, the Network is working with funds provided by the
Maryland Center of Excellence on Problem Gambling to support the Center’s policy and legislative work.
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Upcoming Conference:
Roundtable on Clinical Trials and Access to
Essential Medicines in African Countries
On October 29-30, Law & Health Care Program faculty members Diane Hoffmann and Leslie Meltzer Henry
along with Professor Peter Danchin, Director of Maryland Carey Law’s International and Comparative Law
Program, are hosting a Roundtable on Clinical Trials and Access to Essential Medicines in African Countries.
The meeting is being co-sponsored by the Faculty of Law at Chancellor College in Malawi and will bring
together an international group of legal scholars and medical researchers to examine ethical and legal challenges
to developing and distributing essential medicines in African countries. The by-invitation-only meeting will
focus on four topics:
•

Access to essential medicines as a human right

•

The law and ethics of clinical trials: what rules should govern clinical research in Africa?

•

What do clinical researchers and sponsors owe to host communities?

•

Legal regimes and obstacles: free trade, intellectual property, and access to medicine

In addition to Maryland Carey Law faculty, panelists include:
•

Danwood Chirwa, professor, University of Cape Town Law Faculty

•

Hilda Kaluwa Soko, law lecturer, University of Malawi Chancellor College of Law

•

Lucie White, professor, Harvard Law School

•

Victor Mwapasa, associate professor, University of Malawi College of Medicine

•

Miriam Laufer, associate professor, University of Maryland School of Medicine

•

Mark Barnes, partner, Ropes & Gray, LLP

•

Joseph Mfutso-Bengo, professor of Bioethics and director of the Centre for Bioethics, University of
Malawi College of Medicine

•

David Wendler, senior investigator and head of the Section on Research Ethics, NIH

•

Seema Shah, faculty bioethicist, NIH

•

Chikosa Banda, faculty of Law, University of Malawi Chancellor College of Law

•

Lisa Forman, assistant professor, University of Toronto Law School

•

Heinz Klug, professor and director, Global Legal Studies Center, University of Wisconsin

The roundtable is partially funded by the University of Maryland Baltimore Center for Global Education
Initiatives which has supported collaboration between the Faculty of Law at Chancellor College in Malawi and
Maryland Carey Law since 2010. In 2013, L&HCP Director Diane Hoffmann and Maryland Carey Professor
Peter Danchin traveled to Malawi to host a joint workshop on HIV/AIDS legal issues with Chancellor College
faculty and students. Following that visit, law faculty and students from both schools have made several trips
across the Atlantic to learn from each other and share experiences in legal education. This roundtable is the
latest initiative of this unique collaborative relationship.
The roundtable is also supported by the generous support of Alan & Nancy Eason; the Stuart Rome Lecture
Fund; the Reuben Shiling Mental Health Law Fund; the Leonard C. Homer/Ober|Kaler Law and Health Care
Fund; and the Dr. Richard H. Heller Fund
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Professor Amanda Pustilnik and other L&HCP Faculty
Blog on Pain Imaging and the Law
L&HCP Professor Amanda Pustilnik, a nationally recognized scholar on law
and neuroscience, recently hosted a series of blog posts on the topic of pain
imaging and the law for Harvard Law School’s Bill of Health blog. The series
was partly derived from three symposia Pustilnik has been involved with over
the last 18 months. The first was in April 2014 at the University of Maryland
called “Imaging the Brain, Changing Minds: Chronic Pain Neuroimaging and
the Law.” This meeting brought together pain neuroimaging researchers, legal
decision-makers, and legal scholars for a cross-disciplinary dialog regarding
the potential impact of neuroimaging on legal and cultural norms and led to a
number of publications authored by Pustilnik (listed in the Faculty Highlights
section, page 19).
In April 2015, while Pustilnik was the inaugural Senior Fellow in Law &
Applied Neuroscience at Harvard Law School and a faculty member at the
Center for Law, Brain & Behavior (CLBB) at Massachusetts General Hospital,
she participated in a conversation among experts called “Models of the Mind:
How Neuroscience, Psychology, and the Law Collide.” This meeting, which took place at Harvard Law School,
convened experts in neuroscience, psychology, and the law to discuss three distinct models on the causes of
human behavior and how these three models understand cause and effect, attribute blame, and think about
rehabilitation. Finally, in June 2015, Professor Pustilnik spoke at a public symposium sponsored by CLBB and
Harvard’s Petrie-Flom Center called “Visible Solutions: How Neuroimaging Helps Law Re-envision Pain” that
brought together the leading experts in neuroscience and law to wrestle with the critical question: what can, and
should, the law do with what we know about pain and the brain?
To develop the series of blog posts, Pustilnik recruited L&HCP Professors Frank Pasquale and Diane Hoffmann
to contribute along with other law faculty and pain researchers. Hoffmann, who has written extensively about
legal issues surrounding pain treatment, used the blog post to call for a federally-funded ELSI (ethical, legal,
and social implications) program, similar to the ELSI program that accompanied the Human Genome Project, to
study potential consequences of brain-based pain imaging. L&HCP Professor Frank Pasquale discussed some of
the political and sociological underpinnings of the impulse to measure and quantify pain and the potential risk of
doing so to individuals with disabilities. Pustilnik provided introductory and concluding posts. The blogposts
are available at the links below:
What Should the Future Look Like for Brain-Based Pain Detection? Three Eminent Scholars Weigh In,
by Amanda C. Pustilnik
http://blogs.law.harvard.edu/billofhealth/2015/07/31/what-should-the-future-look-like-for-brain-based-painmeasurement-in-the-law-three-eminent-scholars-offer-their-views/
An ELSI Research Program for Pain Research: A Call to Action, by Diane Hoffmann
http://blogs.law.harvard.edu/billofhealth/2015/07/31/an-elsi-program-for-pain-research-a-call-to-action
Of Algorithms, Algometry, and Others: Pain Measurement and the Quantification of Distrust,
by Frank Pasquale
http://blogs.law.harvard.edu/billofhealth/2015/07/31/of-algorithms-algometry-and-others-pain-measurement-thequantification-of-distrust/
Neuroimaging as Evidence of Pain: It's Time to Prepare, by Hank Greely
http://blogs.law.harvard.edu/billofhealth/2015/07/31/neuroimaging-as-evidence-of-pain-its-time-to-prepare/
Other contributors to the series of blogposts include Karen Davis, Martha Farah, David Seminowicz, and Francis
X. Shen.
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Law & Health Care Program Celebrates Graduation
of 30 Students

2015 Health Law Certificate Graduates and L&HCP Faculty

On May 14, Law & Health Care Program (L&HCP)
faculty celebrated the graduation of 30 students
who earned the health law certificate. The breakfast
celebration was held in the law school’s Westminster
Hall with over 90 people in attendance, including
family and friends of the graduates. This year marks
the 30th anniversary of the Law & Health Care
Program and the 18th year that the program has
been awarding certificates to students who complete
the concentration in health law. This concentration
requires that the students take 17 of their 85 law
school credits in health law, participate in a health law
clinic or externship, and write a scholarly paper on a
health law topic.
As part of the celebration, faculty members came
to the microphone to share the accomplishments of
each of the students. The comments they made, many
of which included funny stories and fond memories,
revealed an incredibly broad range of interests among
the 2015 graduates. Their enthusiasm and energy
enriched the program and inspired everyone in
attendance. Below we highlight five of the students
who received the health law certificate this year.
Nikita M. Floore
Nikita Floore came to the law school with a BA
in English and MS in Rehabilitation Counseling

from Southern Illinois University. Prior to starting
her law studies, she held a number of vocational
rehabilitation positions at the U.S. Department of
Veterans Affairs and the Tennessee Department of
Human Services, including her final position as a
Health System Specialist at the VA in Washington,
DC where she managed a $31 million operational
budget for the Office of Primary Care. Her work in
rehabilitation led Nikita to the L&HCP and ensured
that she was a student leader while she was here.
Nikita was a Leadership Scholar and served as an
Admissions Ambassador for the Office of Admissions.
She was also on the board of the Student Health Law
Organization (SHLO) and participated in the Maryland
Carey Service Corps trip to the Delta Region of
Mississippi. She was able to travel back to Southern
Illinois University as a participant in the Health
Law Moot Court Competition sponsored by SIU’s
law school. Nikita spent her second summer at the
American Health Lawyers Association as a Diversity
Fellow and was very active while in law school with
the Black Law Students Association. Professor Frank
Pasquale who had Nikita for Health Care Law &
Policy and Administrative Law told the audience at
the graduation breakfast, “Nikita has been a leader in
the health law program. She has brought extraordinary
real-world experience to both my classes. I will
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always remember Nikita as one of the most inspiring,
dynamic, insightful, and professional students I’ve
ever known.” Nikita now works at FDA as Regulatory
Counsel in the Center for Tobacco Products where
she is responsible for assisting in the resolution of
compliance issues concerning the application of the
Tobacco Control Act.

Professsor Leslie Meltzer Henry, 2015 Graduate Amy
Dobrzynzki and L&HCP Director Diane Hoffmann
(from l to r)

Sean Gugerty
Sean Gugerty established himself as a leader in the
health law program from the minute he stepped on
campus. In his first semester, when L&HCP Director
Diane Hoffmann asked for student volunteers,
Sean took part in an initiative with the School of
Medicine in which students from both schools were
asked to work together on an end-of-life scenario
and brainstorm about medical and legal solutions.
His willingness to take this on in his first year is
absolutely consistent with the type of student Sean
was - dedicated, curious, bright, and helpful. There
was rarely a time that L&HCP faculty reached out to
students for help that the first response did not come
from Sean. He was student chair for the law school’s
Health Law Regulatory and Compliance Competition,
on the Executive Committee of the Moot Court Board,
and Notes & Comments Editor for the Journal of
Health Care Law & Policy. He also represented the
law school at the Loyola University Chicago School
of Law’s Health Law Transactional Competition. At
the celebration, Professor Kathleen Hoke said to the
assembled group, “Sean was a student in my Public
Health Law Clinic, so we spent quite a lot of time
together over the course of the semester. And it was all
to my benefit! Sean is not only bright, hard-working
and impressively professional; he is also genuinely
nice and engaging.” Sean is now clerking for Judge

Sherrie R. Bailey in the Circuit Court for Baltimore
County.
Ethan Han
Ethan came to Maryland Carey Law with a BA in
Political Science from University of Michigan which
clearly instilled in him the networking skills of a
seasoned politician. Ethan may have set a record
for the number of health law-related internships,
externships and experiences he had as a student at the
law school. He externed at a medical-legal partnership
called Project HEAL at Baltimore’s Kennedy Krieger
Institute and at the Pacific Islander American Health
Forum in Bethesda, Maryland. He interned (not for
credit) at Dimensions Healthcare System and at the
American Podiatric Medical Association. He was
also a research assistant for L&HCP faculty member
Deborah Weimer, a student attorney in the Public
Health Law Clinic, and a member of the Executive
Board of the Student Health Law Organization
(SHLO). Finally, he found time to join Sean
Gugerty as a teammate for the Loyola University
Chicago School of Law’s Health Law Transactional
Competition where the team came in third place.
Virginia Rowthorn, Managing Director of the L&HCP,
said of Ethan, “There has not been a single SHLO
event or initiative that Ethan didn’t help organize
(or at least it seemed that way). He will be missed
tremendously.” This year Ethan is clerking with Judge
Alfred Nance of the Maryland Circuit Court.

2015 Graduate Kelsey-Anne Fung with her parents
and Professor Frank Pasquale (from r to l)

Jaclyn A. Machometa
Jaclyn was recently selected to spend the year as
a Postgraduate Business Fellow at the University
of Maryland Medical System in the Office of the
Legal Counsel (see box, page 10). Jaclyn’s law
school resume made this honor a natural fit. Jaclyn
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was the Managing Editor of the Maryland Law
Journal of Race, Religion, Gender and Class, Vice
President of the Women’s Bar Association, awarded
a Maryland Public Interest Law Project grant, and,
upon graduation, winner of the Joseph Bernstein
Award for written journal submissions for an article
titled, “Round up the Usual Suspexts: Advocating for
Leniency on Consensual, Teenage Sext Offenders” (
MD. J. Race, Religion, Gender & Class (Fall 2014)).
She also externed at the Johns Hopkins Hospital
System and at University of Maryland Medical System
while she was a student. But these accomplishments
and activities do not reflect the passion for social
justice that Jaclyn was known for. Some of her
most important experiences during law school were
her time as a student Attorney in the Civil Rights of
Persons with Disabilities Clinic and as a Fellow at
Project HEAL (Health, Education, Advocacy, and
Law) a medical-legal partnership supported by the
Maryland Volunteer Lawyers Service (MVLS) and the
Johns Hopkins Children’s Center. Jaclyn is committed
to working for social justice and plans to find a job
in this field when her Fellowship ends. As her clinic
professor Marc Charmatz noted, “We’re very sad
she’s graduating, but thrilled to see the health law field
receive such a competent and committed advocate.”
Neha Patel
Neha Patel is a truly gifted student of both pharmacy
and law. She graduated with a PharmD and JD in
May and just started as an Associate at Arnold &
Porter in their FDA and Healthcare practice. Neha
excelled in both schools. At the School of Law, she
was active in SHLO and represented the law school
at our own Health Law Regulatory and Compliance
Competition. At the School of Pharmacy, she won

2015 Graduates Ashley Woolard, Theresa Mahfood,
Oyinladun Adeleye and Nikita Floore (from l to r)

3rd Place in the University of Maryland's Center of
Excellence in Regulatory Science and Innovation
Competition, was on the Dean’s List (top 3%), and
won the Student Government Association Leadership
Award among other accolades. Although she took
classes simultaneously at both schools, she was
able to fully immerse herself as a scholar in both
communities. In addition to interning twice in the
FDA Commissioner’s office (once in the Office of
Policy and Planning and once in the office of Health
and Constituent Affairs), she was a student research
assistant in the School of Pharmacy’s Center on Drugs
and Public Policy. Neha wrote a paper for Professor
Frank Pasquale on drug-drug interaction alerts that
was, according to him, “a truly thoughtful, important
contribution to the field. It offered a smart, sensible
way of tiering alerts so as to reduce physician and
pharmacist ‘alarm fatigue’ while simultaneously
anticipating liability concerns.” He also predicted that
“Neha is going to be a leader in the field of health law
and policy, bringing deep expertise in both law and
science to the most pressing problems.”

2015 health law certificate recipients
Oyinladun O. Adeleye
Lindsay Erin Bramble

Ethan Han

Nicholas Rodriguez

Andrés Heiney-González

Jason Alan Ruben

Evelyn Castillo

Grant Herdrich

Mellissa Sager

Amy Dobrzynski

Lindsey E. Imus

Samantha Sherman

Benjamin L. Eastman

Suela John

Darci Marie Smith

Debra Zweier Ehudin

Connie Lee

Michael N. Tennison

Nikita M. Floore

Lindsay Lowe

Trevonne Victoria Walford

Kelsey-Anne C. Fung

Jaclyn A. Machometa

Andrew Weissenberg

Andrew Geltman

Theresa Mahfood

Ashley Woolard

Sean Gugerty

Neha Patel
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30th Anniversary Celebration of the
Law & Health Care Program
Thursday, October 15, 2015
4:00 p.m.
University of Maryland Carey School of Law
Join program alumni, faculty, friends, and staff for an evening
of learning and reminiscing!
Panels moderated by our renowned faculty will examine the past, present, and future of
health law with experts including:
• Joanne Pollak ‘76, senior vice president, general counsel and chief of staff, Johns
Hopkins Medicine
• Sanford Teplitzky, principal, Ober|Kaler
• Jack Schwartz, adjunct professor and former Maryland assistant attorney general and
director of Health Policy Development
• Carolyn Quattrocki, executive director, Maryland Health Benefit Exchange
• Peter Parvis ‘77, principal, Miles & Stockbridge
• Marcus Wang ‘08, general manager and co-founder, ZytoGen, LLC
• David Cade ‘85, CEO, American Health Lawyers Association
The evening will also include a staged reading and facilitated discussion of “Bioethics
in Play: The Drama of DNA,” a play co-authored by Professor Karen Rothenberg that
probes the ethical and legal dimensions of emerging medical technologies.

To register, please go to:
http://maryland-carey-law.ticketleap.com/healthcare30/
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Law & Health Care Program
Faculty Highlights
Leslie Meltzer Henry

Richard Boldt
Publications

Publications

“Perspectives on Outpatient Commitment,” 49 New
England Law Review 39-80 (2014)

“Just Compensation: A No-Fault Proposal for
Research-Related Injuries,” J.L. & Biosciences
(with Megan E. Larkin and Elizabeth R. Pike)
(2015)

“The ‘Voluntary’ Inpatient Treatment of Adults
Under Guardianship,” 60 Villanova Law Review
1-52 (2015)
Presentations and Speaking Engagements
“Restorative Justice and Sentencing Alternatives,
Advanced Topics in Sentencing,” Judicial Institute
of Maryland (March 2015)
Sara Gold
Presentations and Speaking Engagements
Presenter HIV Criminalization: Preparing the Future
Program, JACQUES Initiative of the Institute of
Human Virology at the University of Maryland
School of Medicine (March 31, 2015)
Honors/Appointments
Member, Baltimore City HIV Planning Group and
Commission, Baltimore, Maryland (Commission
sworn in by Mayor Stephanie Rawlings-Blake on
November 5, 2014)
Michael Greenberger
Presentations/Panel Facilitations
“Legal Preparedness after Hurricane Sandy,” Public
Health Law Conference, Atlanta, Georgia (October
16, 2014)
“Legal Aspects of Mass Immunizations and Routine
Vaccination,” Center for Vaccine Development
Vaccinology Course, University of Maryland School
of Medicine (February 18, 2015)
“Legal Issues Arising from Ebola and other Global
Pandemic Diseases,” New York Bar Association’s
Council on International Affairs, New York N.Y.
(February 24, 2015)
Honors/Appointments
Appointment to the National Academies of Science,
Engineering, and Medicine’s Committee on Science,
Technology, and the Law

“Respect and Dignity: A Conceptual Model for
Patients in the Intensive Care Unit,” 5 Narrative
Inquiry Bioethics (Special Issue) 5A (with Cynda
Rushton, Mary Catherine Beach, and Ruth Faden)
(2015)
“Linking Patient Registries and Biorepositories”
in Agency for Healthcare Research and Quality,
Registries for Evaluating Patient Outcomes: A
User’s Guide (with Benjamin Greenberg and Helen
Moore) (4th ed., forthcoming 2015 )
Presentations/Panel Facilitations
“The Ethics of Digital Experimentation,” The
Conference on Digital Experimentation, MIT,
Boston, MA (October 10, 2014)
“The Law and Ethics of Digital Experimentation,”
American Health Lawyers Association and Drexel
School of Law, Philadelphia, PA (October 23, 2014)
“Just Compensation: A No-Fault Proposal for
Research-Related Injuries,” Trans-NIH Bioethics
Advisory Committee (T-NBC), National Institutes of
Health, Bethesda, MD (January 20, 2015)
“Minor Consent: A Survey of State Laws,” at
conference “Examining Mature Minor Consent for
Participation in HIV Prevention Research,” cosponsored by the National Institute of Allergy and
Infectious Disease (NIAID), National Institute of
Mental Health (NIMH), and National Institute of
Child Health and Development (NICHD), Rockville,
MD (June 24, 2015)
Honors/Appointments
Promoted to full Professor of Law with tenure
(effective July 1, 2015)
Diane Hoffmann
Publications
“Laying the Foundation for an Interprofessional,
Comparative Health Law Clinic,” (with C. Banda
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and K. Amuli) 42 J. Law, Med. & Ethics 392 (Fall
2014)
Report to the Maryland Health Services Cost
Review Commission on Defensive Medicine, (with
B. Herring) (February 15, 2015)
“Increasing Access to Dental and Medical Care by
Allowing Greater Flexibility in Scope of Practice,”
(with R. Manski and V. Rowthorn) 105 AJPH 9
(September 2015)
“Stopping Deceptive Health Claims: The Need for
a Private Right of Action under Federal Law” (with
Jack Schwartz) (forthcoming in American J. of Law
& Med.)
Presentations/Panel Facilitations
“Does Research on the Human Microbiome raise
unique ethical or legal issues?” Institute of Medicine
Annual Meeting, National Academy of Sciences
Washington, D.C. (Oct. 19, 2014).
“Religious, Medical, and Legal Perspectives on End
of Life Issues,” Panelist, University of Maryland
Baltimore Interprofessional Conference, Baltimore,
MD (Nov. 10, 2014)
“How will the practice of defensive medicine affect
the ability of the Maryland Health Services Cost
Review Commission to implement its new global
budget reimbursement model?” Maryland Health
Services Cost Review Commission, Baltimore, MD
(Jan. 9, 2015 and March 11, 2015)

Kathleen Hoke
Publications
“Guidelines for Avoiding Pitfalls when Drafting
Juvenile Curfew Laws: A Legal Analysis,” 8 St.
Louis U. Journal of Health Law & Policy 301
(with Elyse R. Grossman) (2015)
Presentations/Panel Facilitations
“Emerging Issues in Public Health Law” at National
Public Health Law Conference, Atlanta, GA
(October 17, 2014)
“The State’s Role in Tobacco Regulation” at the
Food and Drug Law Institute’s Annual Conference,
Washington, DC (April 21, 2015)
Frank Pasquale
Publications
“Privacy, Autonomy, and Internet Platforms,”
in Privacy in the Modern Age (edited by Marc
Rotenberg, Jeramie Scott, and Julie Hurwitz, 2015)
(discussing the Facebook emotional manipulation
experiment)
“Promoting Innovation While Preventing
Discrimination: Policy Goals for the Scored
Society,” 89 Washington Law Review 1413 (2015)
(with Danielle Keats Citron)
“The Algorithmic Self,” 17(1) Hedgehog Review 23
(2015)

Federal Regulation of Probiotics, Microbiota &
Health Workshop, International Life Sciences
Institute, Washington, D.C. (April 27, 2015)

Presentations/Panel Facilitations

“Medically Ineffective Treatment in Maryland,”
Prince George’s Hospital Center CME Lecture,
Cheverly, MD (April 30, 2015)

Commenter on two papers on law and synthetic
biology and law and genetics at Yale Law School’s
Innovation Beyond IP conference (March 28, 2015)

“Federal Regulation of Probiotics: An Analysis
of the Existing Regulatory Framework” at FDA
Symposium, "Linking the Microbiome to Health,
Safety, and Regulation," College Park, MD
(September 29-30, 2015)

Multiple book talks re: The Black Box Society
at Harvard Law School, the Rochester Institute
of Technology, Georgetown University Center
for Privacy and Technology, and the Columbia
University Division of Social Science

Honors/Appointments/Grants

Honors

Grant to study the practice of defensive medicine
for the Maryland Health Services Cost Review
Commission (Jan. 2015)

Named Editor-in-Chief of Laws, a peer-reviewed
journal of legal theory

Awarded two-year NIH Grant (ELSI grant
from NIAID), “Microbiota Transplantation:
Recommendations for a Regulatory Framework”
(June 2015)

Mitchell Lecture: “Who Rules Big Data?,” SUNY
Buffalo Law School (March 27, 2015)

Named, Member of the Advisory Board, Journal of
Legal Education
Named, Member of the Advisory Board, the Data
Competition Institute.
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Amanda Pustilnik
Publications
“Imaging Brains, Changing Minds: How
Neuroimaging Can Transform the Law’s Approach
to Pain,” 66 Ala. L. Rev. 1099 (2015)
19 J. Health Care L. & Pol’y 1 (2015) (symposium
issue)
•
•
•
•

“Legal and Neuroscientific Perspectives on
Chronic Pain”
“‘Excess Pain’ and the Reasonable Suffering
Standard in Disability Law”
“Chronic Pain, “Psychogenic” Pain, and
Emotion in Tort and Disability”
“Translational Expectations & Issues: Making
it Work in Practice”

“Let’s Stamp Out Perversion: Against the Abuse of
Civil Commitment for the Post-Carceral Detention
of “Sexually Violent Predators” blog post on cato
unbound (Cato Institute Blog) (June 9, 2015)
Karen Rothenberg
Publications
“The Ethical, Legal, and Social Implications
Program of the National Human Genome Research
Institute: Reflections on an Ongoing Experiment”
(with J. McEwen, J. Boyer, K. Sun, N. Lockhart and
M. Guyer), 15 Annual Rev. Genomics Hum. Genet.
481 (September 2014)
The Drama of DNA: Narrative Genomics, (with
L.W. Bush) Oxford Univ. Press (2014)
“Finding Fault? Exploring Legal Duties to Return
Incidental Findings in Genomics Research,” (with
E.R. Pike and B.E. Berkman), 102 Georgetown L.J.
795 (2014)
“Setting the Stage: Enhancing Understanding of
Bioethical Challenges with Theatre,” 11 Ind. Health
L. Rev. 1 (2014)

Presenter and Facilitator (with L. Bush), “Clinical
Genomics in Play: The Drama of DNA”, Festival of
Genomics, Frontline Genomics, Boston, MA (June
23, 2015)
Invited participant, Workshops on Privacy and Trust,
Precision Medicine Initiative, White House Office
of Science and Technology Policy, (March and July
2015)
Virginia Rowthorn
Publications
“All Together Now: Developing a Team Skills
Competency Domain for Global Health Education,”
42 Journal of Law, Medicine & Ethics 550 (2015)
(with Jody Olsen).
“Identifying Interprofessional Global Health
Competencies for 21st Century Health
Professionals,” 81 Annals of Global Health 239
(2015) (with others).
“Putting the Pieces Together: Creating and
Implementing an Interprofessional Global Health
Grant Program,” Health Care: The Journal of
Delivery Science and Innovation (Global Health
Issue) (with Jody Olsen) (forthcoming Winter 2015)
Ellen Weber
Presentations
“Licensure Standards for Opioid Treatment
Programs and Compliance with the Americans With
Disabilities Act,” Testimony before the Maryland
Senate Finance Committee and House Heath and
Government Operations Committee (Feb. 18 and
March 31, 2015)
“Mental Health Parity and Addiction Equity Act,”
Testimony before the Maryland Senate Finance
Committee and House Health and Government
Operations Committee (Feb. 25 and 26, 2015)

Presentations/Panel Facilitations

Honors/Appointments/Grants

Presenter and Facilitator (with L. Bush), “Bioethics
in Play: The Drama of DNA”, Berman Institute
of Bioethics Intensive, Johns Hopkins University,
Baltimore, MD (June 4, 2015)

Weber’s Drug Policy and Public Health Solutions
Clinic was also awarded a third two-year grant from
the Open Society Institute-Baltimore for $280,000
to help establish a medical-legal partnership with
two drug treatment programs to address insurance
coverage issues and access to health services.

Presenter, “All the World’s a Stage: Exploring
Bioethical Challenges with Theatre”, Cultural
Programs of the National Academy of Sciences,
Performing Science, DC Art Science Evening
Rendezvous, Washington, DC (June 18, 2015)
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Law & Health Care Program
500 West Baltimore Street
Baltimore, MD 21201
www.law.umaryland.edu/healthlaw
Comments and letters should be
forwarded to the above address.

Support the Law & Health Care Program
The Law & Health Care Program has hosted a number of hallmark meetings and roundtables to bring
together health care practitioners, legal academics, medical experts, scientists, and policymakers to
examine cutting-edge issues in health policy, law, or ethics. Over the next 30 years, we hope to count you
as a partner in this effort. We plan to build on the stellar foundation we have created as health law educators
to keep asking questions and pushing the field of health law forward. In order to do this, we are asking for
your support. Every contribution helps our program achieve its goals.
There are two ways to give to the Law & Health Care Program:
~ Online at http://www.law.umaryland.edu/give/healthlaw
~ Mail, by sending a check made payable to: UMBF, Inc./ Law & Health Care
to 620 West Lexington Street, 2nd Floor, Baltimore, MD 21201
Funds for the Law & Health Care Program are administered by the University of Maryland, Baltimore Foundation, Inc.

20 │ Law & Health Care Newsletter

